Clinerion’s Patient Network Explorer adds new, actionable functionality to support clinical trial sponsors during site selection as a result of Clinerion’s collaboration with LongTaal, a clinical trial informatics company. The platform now shows current and historical clinical trial performance data for all partner hospitals and trial sites in Clinerion’s worldwide patient network.
Effective immediately, users of Clinerion’s Patient Network Explorer can review detailed clinical trial statistics on an individual hospital level. Derived and mapped from multiple public sources, this new functionality allows for browsing, filtering, reviewing, and comparing site trial performance statistics, including breakdowns on studies by sponsor, by condition, by trial phase and by recruitment status.
The possibility to further filter by study status, sponsor, phase, or condition offers detailed results and a list of the respective studies which provides more information such as on other locations where the study is being conducted.
“It is crucial, during site selection, to have as much information at hand as possible, to avoid expensive detours and dead ends,” says Ian Rentsch, CEO of Clinerion. “Patient Network Explorer is becoming everything a sponsor needs to identify the right site for their trials.”
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.